- Home
- IDCC vs JAZZ Comparison
IDCC vs JAZZ Comparison
Compare IDCC & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDCC
- JAZZ
- Stock Information
- Founded
- IDCC 1972
- JAZZ 2003
- Country
- IDCC United States
- JAZZ Ireland
- Employees
- IDCC N/A
- JAZZ N/A
- Industry
- IDCC Multi-Sector Companies
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- IDCC Miscellaneous
- JAZZ Health Care
- Exchange
- IDCC Nasdaq
- JAZZ Nasdaq
- Market Cap
- IDCC 6.9B
- JAZZ 8.2B
- IPO Year
- IDCC N/A
- JAZZ 2007
- Fundamental
- Price
- IDCC $372.01
- JAZZ $135.18
- Analyst Decision
- IDCC Strong Buy
- JAZZ Strong Buy
- Analyst Count
- IDCC 1
- JAZZ 14
- Target Price
- IDCC $350.00
- JAZZ $179.21
- AVG Volume (30 Days)
- IDCC 432.7K
- JAZZ 653.6K
- Earning Date
- IDCC 10-30-2025
- JAZZ 11-05-2025
- Dividend Yield
- IDCC 0.65%
- JAZZ N/A
- EPS Growth
- IDCC 43.26
- JAZZ N/A
- EPS
- IDCC 14.28
- JAZZ N/A
- Revenue
- IDCC $892,584,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- IDCC N/A
- JAZZ $5.70
- Revenue Next Year
- IDCC N/A
- JAZZ $6.16
- P/E Ratio
- IDCC $25.69
- JAZZ N/A
- Revenue Growth
- IDCC 21.83
- JAZZ 4.52
- 52 Week Low
- IDCC $144.46
- JAZZ $95.49
- 52 Week High
- IDCC $369.58
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- IDCC 71.97
- JAZZ 56.40
- Support Level
- IDCC $359.94
- JAZZ $133.41
- Resistance Level
- IDCC $353.61
- JAZZ $137.43
- Average True Range (ATR)
- IDCC 11.13
- JAZZ 3.08
- MACD
- IDCC -0.20
- JAZZ -0.56
- Stochastic Oscillator
- IDCC 85.64
- JAZZ 39.63
About IDCC InterDigital Inc.
InterDigital Inc is a research and development company focused on wireless, video, Artificial Intelligence, and related technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, out of which the majority is from China.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.